Cutera (Cutera) Interest Expense : $-11.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Cutera Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cutera's interest expense for the three months ended in Dec. 2023 was $ -2.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cutera's Operating Income for the three months ended in Dec. 2023 was $ -44.3 Mil. Cutera's Interest Expense for the three months ended in Dec. 2023 was $ -2.9 Mil. Cutera did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cutera Interest Expense Historical Data

The historical data trend for Cutera's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutera Interest Expense Chart

Cutera Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.20

-0.65

-3.08

-5.66

-11.78

Cutera Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.99	-2.94	-2.96	-2.94	-2.94

Cutera Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.8 Mil.

Cutera (NAS:CUTR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cutera's Interest Expense for the three months ended in Dec. 2023 was $-2.9 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-44.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $427.6 Mil.

Cutera's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Cutera did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cutera (Cutera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

TJ9:Germany

Address

3240 Bayshore Boulevard, Brisbane, CA, USA, 94005

Website

https://www.cutera.com

Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.

Executives

Taylor C. Harris	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond	officer: Interim Chief Financial Office	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones	officer: Chief Operating Officer	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan	director	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry	director, officer: Chief Executive Officer	9775 TOLEDO, IRVINE CA 92618
Rohan Seth	officer: Chief Financial Officer	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea	director	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park	director	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann	director	1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants	director	ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters	director
Sheila Hopkins	director	C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016